Mon, Jun 2, 10:04 AM (42 days ago)
**Liminatus Pharma, Inc. (LIMN) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** Liminatus Pharma, Inc. reported no revenue for the quarter ended March 31, 2025, as the company had not engaged in any operations or generated any revenues. - **Profit Margins:** The company reported a net loss of $255,000 for Q1 2025, primarily due to franchise tax expenses and related penalties. - **Cash Flow:** The company had no cash flows from operating activities, as all activities were related to organizational and business combination efforts. - **Earnings Changes:** The net loss increased slightly from $247,000 in Q1 2024 to $255,000 in Q1 2025. **Quarterly Performance Discussion:** - The company's primary activity during Q1 2025 was facilitating the business combination with Liminatus Pharma, LLC, which was completed on April 30, 2025. - Post-combination, the company expects to incur additional expenses related to being a public company, including legal, financial reporting, accounting, and auditing compliance efforts. **Trends and Uncertainties:** - The company faces substantial doubt about its ability to continue as a going concern twelve months from the issuance date of these financial statements. - The company does not have any long-term debt, lease obligations, or long-term liabilities as of March 31, 2025. - The company is subject to income tax examinations by major taxing authorities, which may include questioning the timing and amount of deductions. **Future Operations Impact:** - Following the business combination, the company will focus on its new operations as Liminatus Pharma, Inc. - The company expects to increase its expenses related to being a public company and will need to secure additional funding to support its ongoing operations and growth strategies. **Key Metrics:** - **Total Assets:** Not disclosed (likely minimal due to the company's focus on the business combination). - **Total Liabilities:** Not disclosed (likely minimal due to the company's focus on the business combination). - **Stockholder's Deficit:** Increased from $(805,000) in Q1 2024 to $(1,060,000) in Q1 2025. **Conclusion:** Liminatus Pharma, Inc. is in the early stages of its operations following the business combination. The company faces financial challenges and uncertainties but has the potential for growth as it transitions to its new operations. Investors should closely monitor the company's progress and financial performance in the coming quarters.